Genomics companies in the U.S. received $2.52 billion in venture capital funding in 2017, up 142 percent from $1.04 billion in 2016, according to a joint report by PwC and CB Insights.
The majority of the $2.52 billion in funding, roughly $1.7 billion, went toward companies focused on disease diagnosis. The second most-funded genomics sector was biotechnology at $550 million.
Here are the five genomics companies that received the most VC funding during the fourth quarter of 2017.
1. Menlo Park, Calif.-based Grail: $238 million
2. South San Francisco, Calif.-based Counsyl: $80 million
3. Baltimore-based Personal Genome Diagnostics: $65 million
4. Burlingame, Calif.-based Color Genomics: $37 million
5. Atlanta-based Prelude Fertility: $10 million